|
Abnormality of chromosome stability
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Adenocarcinoma of lung (disorder)
|
0.310 |
Biomarker
|
disease |
BEFREE |
The ratio of FoxA1 to FoxA2 in lung adenocarcinoma is regulated by LncRNA HOTAIR and chromatin remodeling factor LSH.
|
26658322 |
2015 |
|
Adenocarcinoma of lung (disorder)
|
0.310 |
Biomarker
|
disease |
CTD_human |
c-Myc targeted regulators of cell metabolism in a transgenic mouse model of papillary lung adenocarcinoma.
|
27602772 |
2016 |
|
Adult Glioblastoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Up-regulation of transcription factor E2F1 in astrocytomas and glioblastoma was associated with the progression of gliomas and correlated with LSH expression.
|
28042322 |
2017 |
|
Adult Glioblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Collectively, targeting HELLS may permit the functional disruption of the relatively undruggable MYC and E2F3 transcription factors and serve as a novel therapeutic paradigm for glioblastoma.
|
30779712 |
2019 |
|
Adult Medulloblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Elucidation of HELLS as one of the downstream effectors of the SHH pathway may lead to novel targets for precision therapeutics with the promise of better outcomes for SHH medulloblastoma patients.
|
31541170 |
2019 |
|
Agammaglobulinemia
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Anemia
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Astrocytoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Up-regulation of transcription factor E2F1 in astrocytomas and glioblastoma was associated with the progression of gliomas and correlated with LSH expression.
|
28042322 |
2017 |
|
Autoimmune Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Our data support a contributory role of altered methylation mechanisms in the pathogenesis of systemic autoimmune disorders and related lymphoproliferative processes and suggest that LSH and DNMT3A should be investigated as candidate upstream mediators of decreased L1 promoter methylation and increased L1 expression.
|
29074164 |
2018 |
|
B-Cell Lymphomas
|
0.010 |
Biomarker
|
group |
BEFREE |
These findings indicate a critical role for LSH as a biomarker and therapeutic target in follicular germinal center B-cell lymphoma.
|
30964110 |
2019 |
|
Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In addition, a decrease of the epigenetic regulator LSH in a breast cancer cell line by siRNA treatment reduced DNA methylation and overcame Pol II stalling, whereas overexpression of LSH in a normal breast epithelial cell line increased DNA methylation and resulted in repression.
|
21880597 |
2011 |
|
Burkitt Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The levels of Ki67, LSH, 5-hmC, and E2F1 were all increased in germinal center B-cell lymphomas when compared with those in normal lymph nodes, and LSH was highly expressed in diffuse large B-cell lymphomas (DLBCLs) and Burkitt lymphomas (BLs) that were positive for Epstein-Barr virus (EBV) infection, indicating that LSH is linked to EBV infection in DLBCL and BL.
|
30964110 |
2019 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
This suggests that while HELLS may serve as a biomarker for tumorigenesis and for RB-E2F pathway status, it is unlikely to serve as a relevant target for therapeutics in osteosarcoma.
|
30220967 |
2018 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Linking expression of FOXM1, CEP55 and HELLS to tumorigenesis in oropharyngeal squamous cell carcinoma.
|
22109759 |
2011 |
|
Carcinoma of lung
|
0.030 |
Biomarker
|
disease |
BEFREE |
GINS4 facilitates lung cancer progression by promoting key characteristics of tumor potential, and LSH epigenetically interacts with and stabilizes GINS4 transcripts.
|
31253190 |
2019 |
|
Carcinoma of lung
|
0.030 |
Biomarker
|
disease |
BEFREE |
Finally, we demonstrated that LSH functioned as an oncogene in lung cancer <i>in vitro</i> and <i>in vivo</i>.
|
28900510 |
2017 |
|
Carcinoma of lung
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
This study demonstrates that BaP promotes proliferation by activation of AhR, which promotes SMARCA6 expression, and may identify new diagnostic and therapeutic targets in lung cancer.
|
30094095 |
2018 |
|
Cellular immunodeficiency
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Childhood Glioblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Collectively, targeting HELLS may permit the functional disruption of the relatively undruggable MYC and E2F3 transcription factors and serve as a novel therapeutic paradigm for glioblastoma.
|
30779712 |
2019 |
|
Childhood Glioblastoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Up-regulation of transcription factor E2F1 in astrocytomas and glioblastoma was associated with the progression of gliomas and correlated with LSH expression.
|
28042322 |
2017 |
|
Childhood Medulloblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Elucidation of HELLS as one of the downstream effectors of the SHH pathway may lead to novel targets for precision therapeutics with the promise of better outcomes for SHH medulloblastoma patients.
|
31541170 |
2019 |
|
Childhood Osteosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Further, we pioneered the study of <i>Hells</i> in developmental tumor models by generating Hells conditional knockout osteosarcoma mouse models to examine the role of HELLS in osteosarcoma tumor development.
|
30220967 |
2018 |
|
Clumsiness - motor delay
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Colorectal Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We identified YAP1 as a direct miR-375 target in CRC and show that HELLS and NOLC1 are down-stream targets.
|
24892549 |
2014 |